When a product changes its name

A name is a lookup key before it is anything else

Almost every check a careful buyer can run starts by typing a name into something.

What a seller charged three months ago is filed under a name. What earlier buyers said is filed under a name. What a regulator has published about the substance is filed under a name. What has been studied, and on what, is filed under a name.

None of those records is attached to the container. They are attached to a string of characters, and the string is chosen by whoever is selling.

That is the mechanism. A rename does not have to hide anything to be effective. It only has to break the key.

What survives a rename and what does not

The two halves come apart cleanly, and knowing which is which tells you where to look.

A substance's regulatory position follows the substance. Federal lists of bulk substances are organized one substance at a time, each with its own entry and its own stated reasoning. A product sold under a new name still contains whatever it contained, and that substance keeps its entry. How those lists work is covered separately here.

Published research follows the substance too, for the same reason. A paper describes what was administered, and renaming a retail product does not reach into a journal.

What does not survive is everything about the seller. Price history, cancellation complaints, delivery experiences, the record of how a listing was described last year: all of it is filed under a name that no longer exists on the site.

So the practical rule is that a rename costs you the commercial record and leaves the scientific and regulatory record intact, provided you can find out what the substance is.

A name can change without anything changing, and a substance can change without the name changing

Both directions happen, and they need different checks.

In the first direction the words move and the contents do not. Nothing in the vial is different, and the only thing that has been reset is what a search returns.

In the second direction the words stay and the contents move. A supplier changes, a form changes, a component is added or dropped, and the listing carries the same name it always did.

The first is caught by identifying the substance. The second is caught only by the documents that describe a specific batch, which is what a lot number is for and why a certificate covers one batch rather than a product line.

This is why a name alone, however stable, is not a reason to trust a repeat order. The article on reading a certificate sets out what a batch document does and does not cover.

The rules that keep a name honest, and the label they were written for

Federal law does address a name that hides what a product is, and the wording is worth reading directly.

The labeling of a drug may be misleading, the regulation says, by reason of the employment of a fanciful proprietary name for a drug or ingredient. The clause reaches such a name used in a manner that implies unique effectiveness or composition. It applies where the thing named is in fact a common substance, the limitations of which are readily recognized when it is listed by its established name.

The same regulation names three more ways a name or a list of names can mislead. The order in which ingredient names appear, or the relative prominence given them. Failure to reveal the proportion of an ingredient, or another fact about it, when that fact is material in light of the way the ingredient is featured. And the featuring of inert or inactive ingredients in a manner that creates an impression of value greater than their true functional role.

A fifth clause covers confusion between products. It reaches a drug designated by a proprietary name that, because of similarity in spelling or pronunciation, may be confused with the proprietary name or the established name of a different drug.

Underneath all of that sits the general standard. A drug is misbranded if its labeling is false or misleading in any particular. In deciding whether labeling is misleading, the statute says, account is taken of more than what is stated or suggested. It also takes account of the extent to which the labeling fails to reveal facts that are material in light of those representations.

Why most of those rules stop before your vial

This is the part that changes what the rules above are good for.

A drug dispensed by filling a prescription is exempt from the requirements of the misbranding section, except for a listed handful of paragraphs, provided its label bears five stated items. Those items are the dispenser's name and address, and the serial number and date of the prescription or of its filling. They also include the prescriber's name, the patient's name if the prescription stated it, and the directions and cautionary statements the prescription contained.

The paragraph requiring an established name is not among the exceptions preserved. Neither, therefore, is the regulation written under it, which is where the fanciful-name clause and the prominence rules live.

What is preserved is the first paragraph of the section: false or misleading labeling in any particular. That is a standard about truth rather than about format. It does not prescribe a name, a hierarchy or a type size.

The upshot is narrow and worth stating plainly. On a manufacturer's carton, the law says which name must appear and how large it must be. On a vial dispensed to you, it mostly says only that what appears must not be misleading.

One more definition matters here. Labeling is defined much more broadly than the label, covering written, printed or graphic matter on an article or its containers and matter accompanying it. What a website is, for that purpose, is a question this site does not answer.

Spelling is part of the key, and the spellings do not agree

A name only works as a lookup key if two people write it the same way, and in this market they often do not.

The federal list of bulk substances that may present significant safety risks was read in September 2026. Its entry for one compound this site tracks is written with a lowercase letter where the market writes a capital, and with a capital where the market writes lowercase. A case-sensitive search of that page for any of the three spellings this site's own pages use returns nothing, while the agency's spelling appears four times.

The same list writes another substance three different ways inside a single entry, varying the capitalization of two words from one sentence to the next. It is one entry about one substance. The point is only that the characters are not stable.

The entries also show how many different things a parenthetical after a name can be. On that page one substance is followed by a four-letter abbreviation, another by a laboratory code, and another by a short chemical description. A fourth carries a fragment sequence, with a plain-language note that the substance is also known by a familiar market name.

Nothing here is a criticism of the list, which is doing something harder than it looks. It is a warning about a search. A name search returns what you spelled, and a compound whose spelling is unsettled will be missing from results that would otherwise have told you something.

A mixture with a nickname and no real name

Combined preparations get short trade nicknames more than anything else in this market, and the naming rule for them is specific.

A prescription drug containing two or more active ingredients may bear a proprietary name for the mixture. Where no established name corresponds to that name, the regulation says where the numbers have to go. The quantitative ingredient information must be placed in direct conjunction with the most prominent display of the proprietary name, and its prominence must bear a reasonable relationship to the prominence of that name.

That is the regulation answering the exact problem a nickname creates. If the mixture has no real name, then the amounts have to travel with the invented one, at a comparable size, in the same place.

A separate provision handles a container too small to carry all of it. Even then the label must still bear the proprietary name and the established name if there is one. It must also carry an identifying lot or control number and the name of the manufacturer, packer or distributor, with the full information on the carton or a leaflet.

Read those two together and the shape is clear. The rules never allow the name to travel alone. What a blend hides on the pricing and pharmacology side has its own article here.

A brand name is not the name of the maker

One specific confusion is worth separating out, because a federal agency has published about it directly.

In material addressed to telehealth companies promoting compounded drugs, the agency lists claims it treats as false or misleading. Among them is using branding on a website that falsely or misleadingly implies the telehealth company is the compounder.

The same list names four more. Describing a compounded drug as a generic version of an approved drug, or as the same as one. Claiming it is approved, or has otherwise been evaluated for safety and effectiveness. Describing it as clinically proven to produce the same result as the approved drug. And claiming it is sourced from an approved or licensed pharmacy or outsourcing facility. On that last one the agency states flatly that it does not approve or license any facility.

The point for a reader tracking a name is the first item. A brand on a website is a name for a company's offering, and it is not by itself a statement about who made the contents. Who actually oversees the pharmacy behind a vial is covered separately here.

What to do when a name you were tracking disappears

Find the substance before you look for the product. A sequence, a chemical registry number, or the salt or complex form will survive a rename when a product name will not.

Search the regulatory record by the substance, not by the listing. The lists are organized substance by substance, and they do not know or care what a storefront calls it.

Try more than one spelling, including capitalizations you would not choose yourself. A compound with an unsettled spelling can be absent from a search purely for that reason.

Look at what stayed constant. The operating entity, the address, the terms of service and the pharmacy named in the paperwork are all separate keys, and they change less often than a product name.

Ask directly whether the preparation changed when the name did. It is a fair question, the answer is a fact rather than an opinion, and a seller that will not answer it has told you something.

Treat a missing history as a missing fact rather than a bad sign. A new name is not evidence of anything by itself. It is a reason the usual checks return nothing, which means the checks have to be run another way.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Title 21 Code of Federal Regulations Section 201.10, Drugs; statement of ingredients, read in full including paragraph (c) on the ways an ingredient listing may be misleading, paragraph (h)(1) on a proprietary name for a mixture with no corresponding established name, and paragraph (i) on containers too small to carry the full information — Electronic Code of Federal Regulations, Office of the Federal Register, June 2024
2. United States Code Title 21, Section 352, Misbranded drugs and devices, subsection (a) on labeling that is false or misleading in any particular and subsection (e) on designation of drugs by established names — Office of the Law Revision Counsel, U.S. House of Representatives, September 2026
3. United States Code Title 21, Section 353(b)(2), exempting a drug dispensed by filling a prescription from the requirements of section 352 except the paragraphs it lists, on condition the label bears five stated items — Office of the Law Revision Counsel, U.S. House of Representatives, September 2026
4. United States Code Title 21, Section 321, Definitions, subsection (m) defining labeling and subsection (n) on how the failure to reveal material facts is taken into account in deciding whether labeling is misleading — Office of the Law Revision Counsel, U.S. House of Representatives, September 2026
5. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, read as the source of the spelling census reported above — U.S. Food and Drug Administration, April 2026
6. FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs, including branding that falsely or misleadingly implies the telehealth company is the compounder — U.S. Food and Drug Administration, June 2026